相关实验视频

Updated: Jan 12, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

超出CYP2C19:炎症和血管新生基因变异导致CAD患者的克洛皮多格雷尔耐药性

Foddha Hajer¹, Aouadi Malek², Abderrahmane Amani³

¹Laboratory of Human Genome and Multifactorial Diseases (LR12ES07), Faculty of Pharmacy, University of Monastir, BP N 74, Street Tahar Haddad, 5000, Monastir, Tunisia. hajer.foddha@hotmail.fr.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]

|October 30, 2025

概括

炎症和血管生成途径的遗传变异显著影响冠状动脉疾病患者的克洛皮多格雷尔耐药性. 在CCL5,CCR2和KDR基因中的特定SNP影响治疗反应,建议新的治疗点.

科学领域:

药物基因组学药物基因组学
心血管医学心血管医学
免疫学免疫学免疫学

背景情况:

克洛皮多格雷尔耐药性是冠状动脉疾病 (CAD) 的一个主要临床问题.
虽然CYP450基因多态是已知的因素,但炎症和血管生成途径越来越被认为是血小板反应和药物反应的关键调节器.
这些免疫血管路径中的遗传变异可能导致一些患者的治疗失败.

研究的目的:

研究与炎症相关的基因 (CCR2,CCL5,CCL2) 和血管生成相关的基因 (KDR,VEGFA) 中单核酸多态 (SNP) 之间的关联.
确定这些遗传变异是否有助于冠状动脉疾病患者的克洛皮多格雷尔耐药性.

主要方法:

一项涉及135名突尼斯CAD患者进行双重抗血小板治疗的横截面研究.
使用VerifyNow P2Y12试验评估了克洛皮多格雷尔的反应,耐药性定义为血小板反应率单位 (PRU) 评分≥208.
使用PCR-RFLP对9种特定的SNP进行基因定型,并通过后勤回归分析了与克洛皮多格雷尔耐药性的关联.

主要成果:

CCL5 rs2280789-C等位基因与克洛皮多格勒耐药性风险增加3.4倍相关 (p=0.002).
CCR2 rs1799864-A等位基因表现出一种保护作用 (p=0.02),而KDR rs1870377-AA基因型则增加了抗性几率的三倍 (p=0.04).
多基因分析表明,携带两个或两个以上的风险基因型 (CCR2-GG,CCL5-TC,KDR-AA) 显著增加了耐药性,影响了53%的非响应者与15%的响应者 (p<0.001).

结论:

克洛皮多格雷尔耐药性受到超越CYP450代谢的免疫血管机制的影响,涉及与炎症相关的基因 (CCL5,CCR2) 和血管生成 (KDR/VEGFR2).
在CCL5,CCR2和KDR的遗传变异在调节血小板反应性和克洛皮多格雷尔反应中发挥作用.
这些发现支持开发精确的抗血小板策略,其中包括炎症和血管性通路的基因分析,以优化CAD患者的治疗疗效.

关键词:

血管新生的产生.CCL5 CCL5 CCL5 CCL5 CCL5 CCL5 CCL5 CCL5 CCL5 CCL5 CCL5 CCL5 CCR2 是一个CCR2 的类型.克洛皮多格雷尔耐药性克洛皮多格雷尔耐药性冠状动脉疾病是一种冠状动脉疾病.遗传的多态化遗传多态化炎症炎症是一种炎症.刚果民主共和国的人民共和国.在VEGFR中,VEGFR是VEGFR.

更多相关视频

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...